Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation (EPARGNE)

University Hospital, Rouen

Status and phase: Completed; Phase 3

Conditions: Kidney Transplantation

Treatments: Drug: Sirolimus

Study type: Interventional

Funder types: Other

Identifiers

NCT00811915

2007/125/HP

Details and patient eligibility

About

The use of tacrolimus in the long term as part of the immunosuppressive regimen after transplantation is associated to complications such as chronic nephrotoxicity, impaired glucose metabolism (diabetes mellitus) and an increase of the incidence of neoplasia. The conversion from a tacrolimus based therapy to a sirolimus based therapy associated with mycophenolate mofetil could improve the incidence of such complications. The aim of this study is to assess the risk/benefit ratio of this switch performed in stable renal transplant recipient between 12 months and 36 months after transplantation. The incidence of a composite endpoint (worsening of GFR evaluated by MDRD formula, incidence of cancer and diabetes) will be assessed 24 months after conversion.

Full description

Two doses of Sirolimus will be evaluated accorded to the CYP 3A5 genotype. Patients carrying at least CYP 3A5 *1 allele will receive 4 mg per day whereas the others (CYP 3A5 *3/*3) will receive 2 mg.

Enrollment: 65 patients

Sex: All

Ages: 18 to 76 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recipient age ≥18 and ≤ 75 ans.
• Patients having received a first or second renal transplant from a cadaveric or living related donor between 12 and 24 months prior the inclusion.
• Peak panel reactive antibody (PRA) < 30 %
• Patients with a stable renal function during the 3 months prior to inclusion (variation of serum creatinine lower than 20 %)
• Creatinine clearance ≥ 40 ml/mn/1.73 m26.
• Patients receiving as a stable immunosuppressive treatment associating: Mycophenolate mofetil (MPA AUC > 30 mg.h/L) and Tacrolimus with a trough level > 4 ng/ml, with or without corticoids

Exclusion criteria

• Multiorgan recipients
• Patients receiving cyclosporine
• Pregnancy
• Recipients of ABO incompatible graft
• Use of other immunosuppressive drugs.
• Historical peak reactive antibody ≥ 30 %
• Past medical history of humoral rejection, 2 episodes of acute cellular rejection
• Past medical history of sub-clinical rejection on routine allograft biopsy
• Calculated creatinine clearance < 40 ml/mn/1.73 m2
• 24h proteinuria > 1 g/24H
• Patients with severe diarrhea
• HTLV1 or HIV positivity
• Known hypersensitivity to tacrolimus, mycophenolate mofetil, or sirolimus.
• Total white blood cells < 2500/mm3 or hemoglobin < 9 g/dl

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

65 participants in 2 patient groups

Sirolimus

Experimental group

Description:

Group A : Sirolimus introduction and tacrolimus withdrawal * Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. * Sirolimus daily dose according to CYP3A5 genotype CYP3A5\*1/\*1 or \*1/\*3: 4 mg/d CYPY3A5\*3/\*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml

Treatment:

Drug: Sirolimus

B

Active Comparator group

Description:

Tacrolimus (Advagraf) dose to obtain a trough level between 4 and 10 ng/ml

Treatment:

Drug: Sirolimus